Antibodies and related molecules that bind to 161p2f10b proteins

Abstract

Antibodies and molecules derived therefrom that bind to 161P2F10B protein and variants thereof, are described wherein 161P2F10B exhibits tissue specific expression in normal adult tissue, and is aberrantly expressed in the cancers listed in Table I. Consequently, 161P2F10B provides a diagnostic, prognostic, prophylactic and/or therapeutic target for cancer. The 161P2F10B gene or fragment thereof, or its encoded protein, or variants thereof, or a fragment thereof, can be used to elicit a humoral or cellular immune response; antibodies or T cells reactive with 161P2F10B can be used in active or passive immunization.

1 . A method of delivering a cytotoxic agent to a cell that expresses a 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:2, comprising:
 providing a cytotoxic agent, wherein the cytotoxic agent comprises a monoclonal antibody or fragment thereof comprising an antigen binding site that binds specifically to 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:2, and wherein the monoclonal antibody comprises the V H  region of SEQ ID NO:139, from residue 1 to 114 and the V L  region of SEQ ID NO:140, from residue 1 to 108 and a cytotoxin, wherein the antibody or fragment thereof is conjugated to the cytotoxin; and   delivering the cytotoxic agent to the cell.   
     
     
         2 . The method of  claim 1 , wherein the monoclonal antibody is assigned A.T.C.C. Accession No.: PTA-7452. 
     
     
         3 . The method of  claim 2 , wherein the antibody fragment is derived from the monoclonal antibody. 
     
     
         4 . The method of  claim 1 , wherein the monoclonal antibody is a humanized antibody. 
     
     
         5 . The method of  claim 1 , wherein the fragment is an Fab, F(ab′) 2 , Fv, or Sfv fragment. 
     
     
         6 . The method of  claim 1 , wherein the antibody is a fully human antibody. 
     
     
         7 . The method of  claim 1 , wherein the antigen binding site is a murine antigen binding domain. 
     
     
         8 . The method of  claim 1 , which is recombinantly produced. 
     
     
         9 . The method of  claim 8 , wherein the recombinant protein comprises the antigen binding region. 
     
     
         10 . The method of  claim 1 , wherein the cytotoxin is a radioisotope or a toxin. 
     
     
         11 . The method of  claim 10 , wherein the radioisotope is selected from the group consisting of  212 Bi,  131 I,  131 In,  90 Y,  186 Re,  211 At,  125 I,  188 Re,  153 Sm,  213 Bi,  32 P, and Lu. 
     
     
         12 . The method of  claim 10 , wherein the toxin is selected from the group consisting of ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin,  Pseudomonas  exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, glucocorticoid, auristatins, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolostatin, cc1065, and a cisplatin. 
     
     
         13 . A method of inhibiting growth of a cancer cell that expresses a 161P2F10B protein in a subject, comprising:
 administering to the subject a pharmaceutically acceptable amount of a monoclonal antibody or fragment thereof comprising an antigen binding site that binds specifically to the 161P2F10B protein comprising the amino acid sequence of SEQ ID NO:2, and wherein the monoclonal antibody comprises the V H  region of SEQ ID NO:139, from residue 1 to 114 and the V L  region of SEQ ID NO:140, from residue 1 to 108, whereby the antibody or fragment thereof binds to the protein and inhibits the growth of the cancer cell that expresses the protein.   
     
     
         14 . The method of  claim 13 , wherein the monoclonal antibody is assigned A.T.C.C. Accession No.: PTA-7452. 
     
     
         15 . The method of  claim 14 , wherein the antibody fragment is derived from the monoclonal antibody. 
     
     
         16 . The method of  claim 13 , wherein the monoclonal antibody is a humanized antibody. 
     
     
         17 . The method of  claim 13 , wherein the fragment is an Fab, F(ab′) 2 , Fv, or Sfv fragment. 
     
     
         18 . The method of  claim 13 , wherein the antibody is a fully human antibody. 
     
     
         19 . The method of  claim 13 , wherein the antigen binding site is a murine antigen binding domain. 
     
     
         20 . The method of  claim 13 , which is recombinantly produced. 
     
     
         21 . The method of  claim 20 , wherein the recombinant protein comprises the antigen binding region. 
     
     
         22 . The method of  claim 13 , wherein the cytotoxin is a radioisotope or a toxin. 
     
     
         23 . The method of  claim 22 , wherein the radioisotope is selected from the group consisting of  212 Bi,  131 I,  131 In,  90 Y,  186 Re,  211 At,  125 I,  188 Re,  153 Sm,  213 Bi,  32 P, and Lu. 
     
     
         24 . The method of  claim 22 , wherein the toxin is selected from the group consisting of ricin, ricin A chain, doxorubicin, daunorubicin, a maytansinoid, taxol, ethidium bromide, mitomycin, etoposide, tenoposide, vincristine, vinblastine, colchicine, dihydroxy anthracin dione, actinomycin, diphtheria toxin,  Pseudomonas  exotoxin (PE) A, PE40, abrin, abrin A chain, modeccin A chain, alpha sarcin, gelonin, mitogellin, retstrictocin, phenomycin, enomycin, curicin, crotin, calicheamicin, sapaonaria officinalis inhibitor, glucocorticoid, auristatins, auromycin, yttrium, bismuth, combrestatin, duocarmycins, dolostatin, cc1065, and a cisplatin. 
     
     
         25 . The method of  claim 13 , wherein inhibition of cell growth results in reducing tumor growth in the subject. 
     
     
         26 . The method of  claim 25 , further comprising administering radiation in conjunction with the antibody or fragment thereof. 
     
     
         27 . The method of  claim 25 , further comprising administering a chemotherapeutic agent in conjunction with the antibody or fragment thereof. 
     
     
         28 . The method of  claim 25 , further comprising administering a biologically active therapy in conjunction with the antibody or fragment thereof.